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The number of new psychoactive substances (NPS), synthetic cannabinoids (SCs) in particular, is growing constantly. 
Because of the insufficiently explored effects on consumer health, they have become a major problem in the emergency 
departments. They are difficult to identify, and there are no antidotes that could reverse their detrimental effects. We report 
a case of poisoning of a young man who used SCs. The patient was admitted to the emergency department of the Clinical 
Hospital Merkur, Zagreb (Croatia) after sniffing and smoking a herbal product bought on the street. He presented with 
severe cognitive difficulties and visible eye redness. Other symptoms included somnolence, disorientation, loss of 
coordination, unsteady gait, hyporeflexia, stiffness, cramps and cold limbs, blurred vision, teeth grinding, dry mouth, 
tinnitus, fear, suicidal thoughts, impaired focus, memory, and speech, sedation, fatigue, depression, thought blocking, 
and autistic behaviour. His skin was dry, and his mucosa dry and irritated. Herbal products “Rainbow Special” and 
“Luminated Aroma” used by the patient were qualitatively analysed with gas chromatography / mass spectrometry (GC/
MS) after direct extraction with an organic solvent. Solid-phase extraction method was used to analyse serum and urine 
samples. Despite the negative findings of biological samples, mostly due to the limitations of GC/MS, the clinical picture 
infallibly pointed to the poisoning with SCs. This was confirmed by the findings of 5-fluoro AMB (methyl 
2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate) in the herbal products.
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The so called new psychoactive substances (NPS) are 
the analogues or chemical derivatives of controlled, illicit 
drugs designed to produce similar effects but at the same 
time avoid legal prosecution, as their structure differs from 
illegal drugs on national lists (1, 2).
They have emerged on the European market under the 
names internet drugs, designer drugs, legal highs, herbal 
highs, research chemicals, and bath salts (3) over the last 
decade and are grouped as phenethylamines, piperazines, 
synthetic cannabinoids, or cathinones.
Generally, the clinical manifestations and symptoms of 
NPS poisoning include cognitive difficulties, dry mouth, 
anxiety, panic attacks, eye redness, agitation, nausea, 
vomiting, tachycardia, dizziness, chest pain, headache, and 
tinnitus (4). These symptoms usually last 2-6 h after use. 
Testing on animal models showed that NPS inhalation 
disrupts endothelial function and vasodilatation, which 
explains the hypertensive reaction after inhalation (5).
Synthetic cannabinoids
Synthetic cannabinoids do not necessarily have the same 
or similar chemical structure as THC, but their structure 
allows them to bind to the CB1 and CB2 cannabinoid 
receptors, which results in similar effects as those of 
cannabis (6-8). For now, there are seven main structural 
groups: naphtoylindoles (e.g. JWH-018, JWH-073 and 
JWH-398); naphtoylmethyllindoles; naphtoylpyrroles; 
naphtylmethylindens; phenylacetylindoles (e.g. JWH-250), 
cyclohexanols (e.g. CP 47,497), and classic cannabinoids 
(eg. HU-210) (6).
These compounds have become more known to the 
public after the appearance of the product “Spice”, which 
has become very popular among the young population of 
drug users (9). They are also known under the names K2, 
Skunk, Moon Rocks, Galaxy, and Rainbow and usually take 
the form of a powder, resin, oil, or herbal mixture. The usual 
way of consumption is smoking. Sometimes they are mixed 
with marijuana in a joint or, rarely, prepared as an herbal 
infusion to drink. In smart shops, where they are mostly 
sold, all packages containing herbal blends (usually 
weighing 0.5-3 g) say that they are “not for human 
consumption”. The packages, however, do not specify 
chemical substances and their concentrations and quantities, 
which is particularly dangerous because their quantities and 
concentrations may vary a lot in the same product. This is 
why consumers do not have the same reaction after use, 
and may even overdose themselves and die.
To address this safety issue, Croatia placed synthetic 
cannabinoids and other NPS on the list of illegal drugs in 
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December 2014. However, the number of new psychoactive 
substances keeps growing and putting ever greater pressure 
on the emergency departments (10, 11). Physicians who 
work in emergency services are usually the first contact for 
patients who need help and have an extremely important 
role in identifying the problems and providing medical and 
later psychiatric care.
Patients poisoned with NPS pose a particular challenge, 
because the culprit substances are difficult to identify (given 
the emergency department equipment) and the choice of 
best treatment is challenged.
Here we present a case of synthetic cannabinoid 
poisoning in a young man.
CASE REPORT
A 19-year-old man was admitted to the emergency 
department of the Clinical Hospital Merkur, Zagreb 
(Croatia) in early 2016. He was brought there from school 
by ambulance, because the teachers noticed incoherent 
behaviour and suspected drug abuse. He bought the 
substance on the street and consumed it by sniffing and 
smoking. He acknowledged taking such substances 
regularly for a year.
The clinical picture on admission showed severe 
cognitive impairment, such as very slow movements and 
slur, visible eye redness, somnolence, disorientation, loss 
of coordination, unsteady gait, hyporeflexia, stiffness, 
cramps, cold limbs, blurred vision, teeth grinding, dry 
mouth, tinnitus, unexplained fear, suicidal thoughts, loss of 
focus and memory, fatigue, depression, thought blocking, 
and autistic behaviour. His skin was dry, and the mucosa 
were also dry and irritated.
Blood pressure was normal (120/80 mm Hg), but even 
though ECG did not show tachycardia (below 70 beats per 
minute), the T-waves were tall in the precordial leads, 
pointing to an increased sympathetic tone. Laboratory blood 
serum (complete blood count, electrolytes, coagulation, 
urea and creatinine, pH, and liver transaminases, alkaline 
phosphatase, and amylases) and urine tests (qualitative 
analysis of urine sediment and microscopic examination) 
were within the reference ranges. Sodium levels were at 
the lower limit of normal.
After initial opposition, the patient agreed to give blood 
and urine samples for toxicological analyses. Three sets of 
samples, one urine and two blood and urine sets, were taken; 
the first set was sent to the biochemistry laboratory of the 
Clinical Hospital Merkur for screening for benzodiazepines 
and opiates with test strips, and the second, blood and urine 
set, was sent to the Referral Centre of the Clinical Hospital 
Centre Zagreb to confirm screening test findings with gas 
chromatography / mass spectrometry (GC/MS). The third, 
blood and urine set was sent to the Clinical Hospital Centre 
Split (Split, Croatia) to determine NPS presence with 
advanced methodology.
The boy’s mother volunteered background information, 
as she found and brought empty bags of the products 
“Rainbow Special” and “Luminated Aroma” (Figure 1), 
which she would occasionally notice in her son’s room over 
the last few years. She also noticed that her son had 
difficulties learning, concentrating, and following the 
classes at school.
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Figure 1 “Rainbow Special” and “Luminated Aroma” with herbal mix traces
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Results
The urine screening test was negative for the presence 
of benzodiazepines and opiates. Blood and urine tests were 
negative for alcohol.
The GC/MS also found no presence of the common 
illicit drugs.
However, the GC/MS of the herbal products (Figure 1) 
determined the presence of synthetic cannabinoid 5-fluoro 
AMB (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-
carboxamido)-3-methylbutanoate; 5F-AMB) (Figure 2).
After supportive therapy (1500 mL infusion of saline) 
and six hours of observation at the emergency department, 
the patient was discharged in the company of his mother. 
He was stable, and his blood pressure and heart rate normal. 
He was referred to a psychiatrist for further therapy.
DISCUSSION
The main limitation of our study is related to the use of 
the screening test strips and the GC/MS, neither of which 
could precisely characterise the substance(s) responsible 
for the patient’s poisoning in the tested biological samples. 
At the same time, synthetic cannabinoid 5F-AMB was 
found in the herbal products obtained from the patient’s 
mother. The GS/MS reading was compared with the 
readings of 64 NPS reference materials reported by Vaiano 
et al. (14).
The same synthetic cannabinoid, 5F-AMB, was detected 
in a seized material in Croatia in July 2015 and was added 
to the European information system and database on new 
drugs (EDND) shortly afterwards (15). According to reports 
from other European countries that are available on the 
European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) website, this substance had already been seized 
and described in 2014 (16).
Literature data originating from 2015 (17, 18) report 
the presence of 5F-AMB in the biological samples (adipose 
tissue and femoral blood) taken during the autopsy of a 
synthetic cannabinoid poisoning victim.
Andersson et al. (19) determined 17 metabolites of 
5F-AMB in vitro and reported that the microsomal half-life 
and intrinsic clearance of 5F-AMB are very short. In other 
words, it metabolises rapidly. This is one of the reasons 
why it cannot be proven in biological samples, especially 
in the clinical ones after a short while and the most likely 
reason why we did not detect it in the biological samples 
collected from our patient. In such cases, the analysis of 
suspected products, if available, may help to point the 
physician in the right direction for treatment. Another 
helpful pointer would be an atypical clinical picture, 
especially in younger patients, as it raises suspicion of NPS 
consumption (11).
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Two bags of the products “Rainbow Special” and 
“Luminated Aroma” were sent to a laboratory for qualitative 
analysis with GC/MS.
Biosample analysis
For both serum and urine extraction we used solid-phase 
extraction (SPE) with Supelclean Envi Florisil and 
Supelclean LC-18 Reversed-Phase cartridges (Supelco, 
Sigma Aldrich, Taufkirchen, Germany) as well as liquid-
liquid extraction (LLE) with Varian Toxitubes A (Palo Alto, 
CA, USA). All extraction protocols were carried out 
according to the manufacturer’s instructions.
GC/MS drug analysis was performed on a Shimadzu 
GC/MS-QP2010 Ultra with a mass spectrometer detector 
(Shimadzu, Kyoto, Japan). The chromatographic column 
was InterCap 5MS/NP 5 % phenyl, 95 % methyl 
polysiloxane, length 30 m, diameter 0.25 mm, film thickness 
0.25 μm (GL Sciences, Tokyo, Japan). The initial column 
temperature of 90 °C was held for 3 min, then ramped to 
270 °C at 15 °C min-1, held there for 5 min, and then ramped 
again to 320 °C at 15 °C min-1 and held for 27 min. The 
total run time was 50.33 min. For the carrier gas we used ultra-
pure-grade helium at the flow rate of about 1.5 mL min-1. 
Samples were injected using the splitless mode with injection 
temperature of 250 °C. GC/MS analysis was performed using 
full scan MS (40-600 m/z).
Herbal product analysis
Before the analysis, the obtained herbal products were 
subjected to direct extraction with chloroform-ethyl acetate 
1:1 (Merck, Darmstadt, Germany). They were macerated 
for 30 min, filtered, evaporated in nitrogen stream, and 
dissolved in 30 μL of chloroform. The drugs were analysed 
with a Shimadzu GC-2010 GC/MS with a mass spectrometer 
detector. The chromatographic column was RTX–5MS 5 % 
diphenyl, 95 % dimethyl polysiloxane, length 30 m, 
diameter 0.25 mm, film thickness 0.25 μm (Restek, 
Bellefonte, PA, USA). The initial column temperature of 
90 °C was held for 3 min and then ramped to 270 °C at 
20 °C min-1 and held there for 33 min. The total run time 
was 45 min. For the carrier gas we used ultra-pure-grade 
helium at the flow rate of about 1.5 mL min-1. Samples were 
injected using the splitless mode with injection temperature 
of 250 °C. GC/MS analysis was performed using full scan 
MS (40-600 m/z).
Samples were qualitatively analysed with GC/MS using 
the full-scan mode. The readings were compared with the 
Wiley library of Mass Spectra of Designer Drugs (12), the 
free database of the Scientific Working Group for the 
Analysis of Seized Drugs (SWGDRUG) (13), as well as 
with our in-house library containing about 1000 compounds 
and metabolites. Each sample was analysed twice. To verify 
the findings, the chromatograms were sent to the University 
of Florence Department of Health Science, Florence, Italy.
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CONCLUSION
The clinical picture presented here and circumstantial 
evidence (herbal product brought by the mother) pointed 
to the consumption of synthetic cannabinoids but it was not 
confirmed by laboratory findings. Obviously, prompt 
recognition and treatment of NPS poisoning represents a 
major challenge both for the healthcare professionals and 
toxicologists. To efficiently manage such cases, it is very 
important to collect information about possible use of 
psychoactive substances in addition to observing clinical 
manifestations in the patient. It is also very important to 
build a quality network as part of the national early warning 
system that would include emergency services, primary 
health care, and toxicology laboratories that own advanced 
equipment for NPS determination. This would improve 
diagnosis, and possibly lead to an NPS database with 
symptoms related to a specific substance that would be 
available to all interested healthcare professionals.
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Slučaj trovanja sintetskim kanabinoidima u Hrvatskoj
Broj novih psihoaktivnih tvari (engl. new psychoactive substances, krat. NPS), osobito sintetskih kanabinoida (engl. 
synthetic cannabinoids, krat. SC), stalno se povećava. Zbog nedovoljno istraženih učinaka na zdravlje korisnika, te tvari 
stvaraju velike probleme odjelima hitne medicine. Teško je dokazati njihovu prisutnost, a protuotrovi koji bi mogli poništiti 
njihovo štetno djelovanje nisu poznati. Prikazujemo slučaj trovanja mladog muškarca koji je konzumirao sintetske 
kanabinoide. Pacijent je zaprimljen na odjel hitne službe Kliničke bolnice Merkur u Zagrebu nakon šmrkanja i pušenja 
biljnog proizvoda kupljenoga na ulici. Prilikom dolaska u hitnu službu kliničkom slikom dominiraju kognitivne poteškoće 
(izrazito usporenih kretnji, polaganog izgovora), a objektivno je bilo uočljivo izrazito crvenilo očiju. Klinička slika 
bolesnika uključivala je niz različitih simptoma: stanje svijesti – somnolencija; neurološki simptomi – dezorijentiranost, 
gubitak koordinacije, nesiguran hod, hiporefleksija; oftalmološki simptomi – zamagljen vid; ORL simptomi – škripanje 
zubima, suha usta, šumovi u ušima; simptomi srca, krvožilja i dišnog sustava – nije imao; simptomi probavnog sustava 
– gubitak apetita; simptomi mišićno-koštanog sustava – ukočenost, grčevi i hladnoća udova; psihološki simptomi – 
konfuzija, strah, suicidalne misli, poremećaj pažnje, pamćenja i govora, sedacija, umor, depresija, blok misli, autistično 
ponašanje. Koža je bila suha, a sluznice suhe i iritirane. Heteroanamnestičkim podacima od majke, koja je donijela prazne 
vrećice marketinškog imena Rainbow Special i Luminated Aroma doznali smo da slične vrećice nalazi već godinu dana 
u sinovoj sobi, a istom zamjećuje da sin sve teže uči, ne može se koncentrirati i pratiti nastavu. Sin je odbijao prestati s 
konzumacijom. Biljni proizvodi Rainbow Special i Luminated Aroma, koje je pacijent konzumirao nakon izravne ekstrakcije 
s organskim otapalom, kvalitativno su analizirani plinskom kromatografijom / masenom spektrometrijom (GC / MS). 
Metodom ekstrakcije na čvrstoj fazi analizirani su uzorci seruma i mokraće. Unatoč negativnim nalazima bioloških 
uzoraka, uglavnom zbog ograničenja GC / MS metode, klinička je slika nedvojbeno upućivala na trovanje sintetskim 
kanabinoidima. To je potvrđeno i nalazima 5-fluor AMB (metil 2- (1- (5-fluoropentil) -lH-indazol-3-karboksamido) 
-3-metilbutanoata) u biljnim proizvodima.
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